ADC-Pertuzumab Promising as New Standard in HER2-Positive Metastatic Breast Cancer

CHICAGO — First-line trastuzumab deruxtecan (T-DXd) combined with pertuzumab (Perjeta) improved progression-free survival (PFS) in HER2-positive locally advanced or metastatic breast cancer, according to the DESTINY-Breast09 trial. In the phase III study after a median of follow-up of 29 months, patients randomized to T-DXd plus pertuzumab had a median PFS by blinded independent central review […]

Alternative Endpoints in Phase III Trials Don’t Always Mean Boosts to OS, QOL

CHICAGO — Late-phase trials that showed superiority for an experimental intervention on a surrogate endpoint did not necessarily lead to improvements in overall survival (OS) or quality of life (QOL), according to a meta-epidemiologic analysis. Alexander Dean Sherry, MD of the MD Anderson Cancer Center in Houston, and colleagues evaluated 791 randomized controlled trials (RCTs) […]

A Chicago Hospital Bows to Federal Pressure on Trans Care for Teens

He’s 17 and lives in the Chicago suburbs. He loves theater and recently helped direct a play at his high school. He takes competitive AP courses and is working on his Eagle Scout project. And he’s been on a journey for 4 years. Once a week, the transgender teen injects testosterone into his body. He’s […]